US Pneumococcal Vaccine Market Size study, by Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine) by Product (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Products) by End-use (Public Sector, Private Sector) Forecasts 2022-2032
US Pneumococcal Vaccine Market is valued approximately USD 3.67 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.90% over the forecast period 2024-2032. The Pneumococcal Vaccine is a vaccine that protects against infection with pneumonia-causing streptococcus bacteria, also known as pneumococcus. This bacterium can cause infections such as meningitis, pneumonia, and bacteremia (a bloodstream infection). The vaccination works by stimulating the immune system to produce antibodies against certain bacterial strains, preventing infection. Also, increasing emphasis on preventive healthcare and the role of vaccines in reducing disease burden and healthcare costs has contributed to a positive outlook for the pneumococcal vaccine market. Healthcare providers and public health agencies are actively promoting pneumococcal vaccination as part of routine preventive care. Thus, this trend is anticipated to support the growth of US Pneumococcal Vaccine Market.
Moreover, growing awareness among healthcare providers and patients about the importance of vaccination in preventing pneumococcal diseases is a significant driver. Public health campaigns, educational programs, and initiatives by healthcare organizations contribute to this awareness. Also, government initiatives such as vaccination programs, recommendations by the Centers for Disease Control and Prevention (CDC), and inclusion of pneumococcal vaccines in routine immunization schedules for children and adults boost market growth. Government-funded vaccination programs, especially for vulnerable populations, further propel market expansion. Additionally, the prevalence of pneumococcal diseases, including pneumonia, meningitis, and bacteremia, remains a concern in the US. The increasing incidence of antibiotic-resistant strains of Streptococcus pneumoniae underscores the need for effective vaccination, thus driving market growth. However, high manufacturing costs are expected to hinder the market growth during the forecast period 2024-2032.
Major market player included in this report are:
Merck & Co., Inc
Pfizer Inc.
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below:
By Vaccine Type
Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine
By Product
Prevnar 13
Synflorix
Pneumovax 23
Vaxneuvance
Pneumosil
Other Products
By End-use
Public Sector
Private Sector
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
Moreover, growing awareness among healthcare providers and patients about the importance of vaccination in preventing pneumococcal diseases is a significant driver. Public health campaigns, educational programs, and initiatives by healthcare organizations contribute to this awareness. Also, government initiatives such as vaccination programs, recommendations by the Centers for Disease Control and Prevention (CDC), and inclusion of pneumococcal vaccines in routine immunization schedules for children and adults boost market growth. Government-funded vaccination programs, especially for vulnerable populations, further propel market expansion. Additionally, the prevalence of pneumococcal diseases, including pneumonia, meningitis, and bacteremia, remains a concern in the US. The increasing incidence of antibiotic-resistant strains of Streptococcus pneumoniae underscores the need for effective vaccination, thus driving market growth. However, high manufacturing costs are expected to hinder the market growth during the forecast period 2024-2032.
Major market player included in this report are:
Merck & Co., Inc
Pfizer Inc.
Company 3
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10
The detailed segments and sub-segment of the market are explained below:
By Vaccine Type
Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine
By Product
Prevnar 13
Synflorix
Pneumovax 23
Vaxneuvance
Pneumosil
Other Products
By End-use
Public Sector
Private Sector
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
CHAPTER 1. US PNEUMOCOCCAL VACCINE MARKET DEFINITION AND RESEARCH ASSUMPTIONS
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
CHAPTER 2. EXECUTIVE SUMMARY
2.1. US Pneumococcal Vaccine Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Vaccine Type
2.2.2. By Product
2.2.3. By End-use
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
CHAPTER 3. US PNEUMOCOCCAL VACCINE MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
CHAPTER 4. US PNEUMOCOCCAL VACCINE MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. US PNEUMOCOCCAL VACCINE MARKET SIZE & FORECASTS BY VACCINE TYPE 2022-2032
5.1. Pneumococcal Conjugate Vaccine
5.2. Pneumococcal Polysaccharide Vaccine
CHAPTER 6. US PNEUMOCOCCAL VACCINE MARKET SIZE & FORECASTS BY PRODUCT 2022-2032
6.1. Prevnar
6.2. Synflorix
6.3. Pneumovax
6.4. Vaxneuvance
6.5. Pneumosil
6.6. Other Products
CHAPTER 7. US PNEUMOCOCCAL VACCINE MARKET SIZE & FORECASTS BY END-USE 2022-2032
7.1. Public Sector
7.2. Private Sector
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Merck & Co., Inc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Pfizer Inc.
8.3.3. Company
8.3.4. Company
8.3.5. Company
8.3.6. Company
8.3.7. Company
8.3.8. Company
8.3.9. Company
8.3.10. Company
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
CHAPTER 2. EXECUTIVE SUMMARY
2.1. US Pneumococcal Vaccine Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Vaccine Type
2.2.2. By Product
2.2.3. By End-use
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
CHAPTER 3. US PNEUMOCOCCAL VACCINE MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
CHAPTER 4. US PNEUMOCOCCAL VACCINE MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. US PNEUMOCOCCAL VACCINE MARKET SIZE & FORECASTS BY VACCINE TYPE 2022-2032
5.1. Pneumococcal Conjugate Vaccine
5.2. Pneumococcal Polysaccharide Vaccine
CHAPTER 6. US PNEUMOCOCCAL VACCINE MARKET SIZE & FORECASTS BY PRODUCT 2022-2032
6.1. Prevnar
6.2. Synflorix
6.3. Pneumovax
6.4. Vaxneuvance
6.5. Pneumosil
6.6. Other Products
CHAPTER 7. US PNEUMOCOCCAL VACCINE MARKET SIZE & FORECASTS BY END-USE 2022-2032
7.1. Public Sector
7.2. Private Sector
CHAPTER 8. COMPETITIVE INTELLIGENCE
8.1. Key Company SWOT Analysis
8.1.1. Company
8.1.2. Company
8.1.3. Company
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Merck & Co., Inc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Pfizer Inc.
8.3.3. Company
8.3.4. Company
8.3.5. Company
8.3.6. Company
8.3.7. Company
8.3.8. Company
8.3.9. Company
8.3.10. Company
CHAPTER 9. RESEARCH PROCESS
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
LIST OF TABLES
TABLE 1. US Pneumococcal Vaccine market, report scope
TABLE 2. US Pneumococcal Vaccine market estimates & forecasts by Vaccine Type 2022-2032 (USD Billion)
TABLE 3. US Pneumococcal Vaccine market estimates & forecasts by Product 2022-2032 (USD Billion)
TABLE 4. US Pneumococcal Vaccine market estimates & forecasts by End-use 2022-2032 (USD Billion)
TABLE 5. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 6. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. U.S. Pneumococcal Vaccine market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. U.S. Pneumococcal Vaccine market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 12. U.S. Pneumococcal Vaccine market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 13. List of secondary sources, used in the study of US Pneumococcal Vaccine Market.
TABLE 14. List of primary sources, used in the study of US Pneumococcal Vaccine Market.
TABLE 15. Years considered for the study.
TABLE 16. Exchange rates considered
TABLE 1. US Pneumococcal Vaccine market, report scope
TABLE 2. US Pneumococcal Vaccine market estimates & forecasts by Vaccine Type 2022-2032 (USD Billion)
TABLE 3. US Pneumococcal Vaccine market estimates & forecasts by Product 2022-2032 (USD Billion)
TABLE 4. US Pneumococcal Vaccine market estimates & forecasts by End-use 2022-2032 (USD Billion)
TABLE 5. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 6. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 7. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 8. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 9. US Pneumococcal Vaccine market by segment, estimates & forecasts, 2022-2032 (USD Billion)
TABLE 10. U.S. Pneumococcal Vaccine market estimates & forecasts, 2022-2032 (USD Billion)
TABLE 11. U.S. Pneumococcal Vaccine market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 12. U.S. Pneumococcal Vaccine market estimates & forecasts by segment 2022-2032 (USD Billion)
TABLE 13. List of secondary sources, used in the study of US Pneumococcal Vaccine Market.
TABLE 14. List of primary sources, used in the study of US Pneumococcal Vaccine Market.
TABLE 15. Years considered for the study.
TABLE 16. Exchange rates considered
LIST OF FIGURES
FIG 1. US Pneumococcal Vaccine market, research methodology
FIG 2. US Pneumococcal Vaccine market, market estimation techniques
FIG 3. US market size estimates & forecast methods.
FIG 4. US Pneumococcal Vaccine market, key trends 2023
FIG 5. US Pneumococcal Vaccine market, growth prospects 2022-2032
FIG 6. US Pneumococcal Vaccine market, porters 5 force model
FIG 7. US Pneumococcal Vaccine market, pestel analysis
FIG 8. US Pneumococcal Vaccine market, value chain analysis
FIG 9. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 10. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 11. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 12. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 13. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 14. US Pneumococcal Vaccine market, company market share analysis (2023)
FIG 1. US Pneumococcal Vaccine market, research methodology
FIG 2. US Pneumococcal Vaccine market, market estimation techniques
FIG 3. US market size estimates & forecast methods.
FIG 4. US Pneumococcal Vaccine market, key trends 2023
FIG 5. US Pneumococcal Vaccine market, growth prospects 2022-2032
FIG 6. US Pneumococcal Vaccine market, porters 5 force model
FIG 7. US Pneumococcal Vaccine market, pestel analysis
FIG 8. US Pneumococcal Vaccine market, value chain analysis
FIG 9. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 10. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 11. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 12. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 13. US Pneumococcal Vaccine market by segment, 2022 & 2032 (USD Billion)
FIG 14. US Pneumococcal Vaccine market, company market share analysis (2023)
